Perimeter Medical Imaging AI Announces Voting Results from 2022 Annual and Special Meeting of Shareholders
07 Noviembre 2022 - 4:01PM
Business Wire
Perimeter Medical Imaging AI, Inc. (TSX-V: PINK) (OTC: PYNKF)
(FSE: 4PC) (“Perimeter” or the “Company”) – a medical technology
company driven to transform cancer surgery with
ultra-high-resolution, real-time, advanced imaging tools to address
high unmet medical needs, announced the results of its 2022 annual
and special meeting of shareholders (the “Meeting”) held on October
27, 2022.
All the matters put forward before Shareholders for
consideration and approval as set out in the Company’s management
information circular dated September 20, 2022 were approved by the
requisite majority of votes cast at the Meeting, including the
election of all seven management nominees to the board of directors
of the Company for the ensuing year. Perimeter’s board of directors
now consists of:
- Anthony Holler
- Jeremy Sobotta
- Suzanne M. Foster
- Aaron Davidson
- Ian Mortimer
- Hugh Cleland
- Anantha Kancherla
At the Meeting, the shareholders approved the adoption of
Perimeter’s new omnibus equity incentive plan (the “Omnibus Plan”)
and reserved common shares of Perimeter (“Common Shares”) for
issuance under the Omnibus Plan. The Omnibus Plan is a “fixed up to
20% plan” (as that term is used by the TSX Venture Exchange) and
replaces the Company’s previous fixed 20% stock option plan. The
Omnibus Plan allows the Company to issue stock options, restricted
share units, performance share units, deferred share units and
stock appreciation rights (“Awards”). The maximum number of Common
Shares reserved and available for issuance under the Omnibus
Incentive Plan is fixed at an aggregate of 12,834,531 Common Shares
(such number being equal to approximately 20% of the issued and
outstanding Common Shares).
The shareholders also approved the reappointment of the
Company’s auditor KPMG LLP for the ensuing year, and the directors
were authorized to fix the auditors’ remuneration.
About Perimeter Medical Imaging AI, Inc.
Based in Toronto, Canada and Dallas, Texas, Perimeter Medical
Imaging AI (TSX-V: PINK) (OTC: PYNKF) (FSE: 4PC) is a medical
technology company driven to transform cancer surgery with
ultra-high-resolution, real-time, advanced imaging tools to address
areas of high unmet medical need. Available across the U.S., our
FDA-cleared Perimeter S-Series OCT system provides real-time,
cross-sectional visualization of excised tissues at the cellular
level, with 10x greater image resolution than X-ray and ultrasound,
and 100x greater than MRI. The breakthrough-device-designated
investigational Perimeter B-Series OCT with ImgAssist AI represents
our next-generation artificial intelligence technology that is
currently being evaluated in a pivotal clinical trial, with support
from a grant of up to US$7.4 million awarded by the Cancer
Prevention and Research Institute of Texas. The company’s ticker
symbol “PINK” is a reference to the pink ribbons displayed during
Breast Cancer Awareness Month.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
Forward-Looking Statements
This news release contains statements that constitute
“forward-looking information” within the meaning of applicable
Canadian securities legislation. In this news release, words such
as “may,” “would,” “could,” “will,” “likely,” “believe,” “expect,”
“anticipate,” “intend,” “plan,” “estimate,” and similar words and
the negative form thereof are used to identify forward-looking
statements. Forward-looking information may relate to management’s
future outlook and anticipated events or results and may include
statements or information regarding the future financial position,
business strategy and strategic goals, competitive conditions,
research and development activities, projected costs and capital
expenditures, research and clinical testing outcomes, taxes and
plans and objectives of, or involving, Perimeter. Without
limitation, information regarding the potential benefits of
Perimeter S-Series OCT, Perimeter B-Series OCT, and Perimeter
ImgAssist; Perimeter’s expected development activities and the
expected details regarding Perimeter’s ongoing clinical trials are
forward-looking information. Forward-looking statements should not
be read as guarantees of future performance or results, and will
not necessarily be accurate indications of whether, or the times at
or by which, any particular result will be achieved. No assurance
can be given that any events anticipated by the forward-looking
information will transpire or occur. Forward-looking information is
based on information available at the time and/or management’s
good-faith belief with respect to future events and are subject to
known or unknown risks, uncertainties, assumptions, and other
unpredictable factors, many of which are beyond Perimeter’s
control. Such forward-looking statements reflect Perimeter’s
current view with respect to future events, but are inherently
subject to significant medical, scientific, business, economic,
competitive, political, and social uncertainties and contingencies.
In making forward-looking statements, Perimeter may make various
material assumptions, including but not limited to (i) the accuracy
of Perimeter’s financial projections; (ii) obtaining positive
results from trials; (iii) obtaining necessary regulatory
approvals; and (iv) general business, market, and economic
conditions. Further risks, uncertainties and assumptions include,
but are not limited to, those applicable to Perimeter and described
in Perimeter’s Management Discussion and Analysis for the year
ended December 31, 2021, which is available on Perimeter’s SEDAR
profile at www.sedar.com, and could cause actual events or results
to differ materially from those projected in any forward-looking
statements. Perimeter does not intend, nor does Perimeter undertake
any obligation, to update or revise any forward-looking information
contained in this news release to reflect subsequent information,
events, or circumstances or otherwise, except if required by
applicable laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221107006038/en/
Chris Scott Chief Financial Officer Perimeter Medical Imaging
AI, Inc. Investors: investors@perimetermed.com Toll-free:
888-988-7465 (PINK) Jodi Regts Corporate Communications Perimeter
Medical Imaging AI, Inc. Media: media@perimetermed.com Mobile:
469-743-1834
Simplify Exchang (NYSE:PINK)
Gráfica de Acción Histórica
De Mar 2025 a Abr 2025
Simplify Exchang (NYSE:PINK)
Gráfica de Acción Histórica
De Abr 2024 a Abr 2025